Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?

Over 80% of crs with nasal polyps’ patients have type 2 inflammation dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.